.jpeg)
2026-05-20 04:57:13
A comprehensive guide to Niraparib (Zejula), a once-daily PARP inhibitor for maintaining remission in ovarian, fallopian tube, and peritoneal cancers. Learn about HRD selection, dosing by weight, and critical blood monitoring.
2026-05-20 04:44:25
A guide to Abiraterone, a hormonal therapy for metastatic prostate cancer. Learn about its mechanism in blocking androgen synthesis, dosing with Prednisone, and critical safety protocols for liver health and fetal protection.
2026-05-20 03:01:24
A comprehensive guide to Plerixafor (Mozobil), a CXCR4 antagonist used in stem cell transplantation for Non-Hodgkin's Lymphoma and Multiple Myeloma. Learn about dosage, administration, and critical safety protocols.
2026-05-20 02:43:58
Explore the safety profile of Brensoctib, a first-in-class DPP-1 inhibitor for neutrophil-mediated inflammatory diseases. This guide details the management of dermatological, periodontal, and infection risks during treatment.
2026-05-20 02:31:44
Explore the medicinal chemistry and clinical profile of Tivozanib. This guide covers its synthetic route, high selectivity for VEGFR, and role in targeted therapy for advanced kidney cancer.
2026-05-20 02:26:46
A comprehensive guide to Trifluridine/Tipiracil (FTD/TPI), an oral chemotherapy for metastatic colorectal and gastric cancers. Learn about safety profiles, bone marrow suppression, and clinical management strategies.
2026-05-20 02:14:35
Discover how Trelagliptin offers a breakthrough in Type 2 Diabetes management with its once-weekly dosing, superior adherence, stable glycemic control, and long-term safety profile.
2026-05-19 07:04:42
This article details the medication precautions and risk management strategies for the KRAS G12C targeted inhibitor Adagrasib in women of childbearing age, pregnant and lactating women, elderly patients, and patients with underlying comorbidities.
2026-05-18 04:21:15
Olutasidenib (Rezlidhia) is an oral IDH1 mutation inhibitor developed by Rigel Pharmaceuticals. Approved by the FDA in 2022, it is used for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring IDH1 mutations. With definite efficacy and good tolerability, it provides a precise targeted treatment option for such patients.
2026-05-18 04:06:05
Capmatinib, a highly selective MET inhibitor, demonstrates transformative efficacy in METex14-mutated NSCLC. Pivotal GEOMETRY data show significant tumor shrinkage and survival improvement, particularly in brain metastases. Global accessibility through originator and generic options empowers patients, while ongoing combo therapies and resistance research expand future horizons.
2026-05-15 02:57:37
The FDA has granted approval to Teclistamab (Tecvayli) in combination with Daratumumab and hyaluronidase (Darzalex Faspro) for relapsed or refractory multiple myeloma (RRMM). Based on pivotal MajesTEC-3 data, this dual-targeted immunotherapy demonstrates transformative PFS and OS benefits, offering a new standard for heavily pretreated patients. This article dissects the mechanism, trial outcomes, safety profile, and clinical implications, providing actionable insights for global oncology teams.
2026-05-15 02:34:50
Beyond its traditional TKI role, Cabozantinib is reshaping cancer care as a core agent across RCC, RAI-R DTC, HCC, and NETs. This article dissects its expanding indications, synergistic combination strategies, side effect management, and global access dynamics, offering actionable insights for patients and clinicians in the Asia-Pacific and international communities.
